July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
NCL is implicated in the NXNL1 gene splicing and leads to RdCVF expression in retinoblastoma cell lines
Author Affiliations & Notes
  • Najate Ait-Ali
    Institut De la Vision, Paris, France
  • Frédéric Blond
    Institut De la Vision, Paris, France
  • Sunhye Lee
    Saban Research Institute, Children’s Hospital Los Angeles, Los Angeles, California, United States
  • Sijia Wang
    Saban Research Institute, Children’s Hospital Los Angeles, Los Angeles, California, United States
  • David Cobrinik
    Saban Research Institute, Children’s Hospital Los Angeles, Los Angeles, California, United States
    Roski Eye Institute, Keck School of Medicine, USC, Los Angeles, CA, USA, California, United States
  • Thierry D Leveillard
    Institut De la Vision, Paris, France
  • Footnotes
    Commercial Relationships   Najate Ait-Ali, National Institute of Industrial Property (France) (P); Frédéric Blond, None; Sunhye Lee, None; Sijia Wang, None; David Cobrinik, None; Thierry Leveillard, National Institute of Industrial Property (France) (P)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 4940. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Najate Ait-Ali, Frédéric Blond, Sunhye Lee, Sijia Wang, David Cobrinik, Thierry D Leveillard; NCL is implicated in the NXNL1 gene splicing and leads to RdCVF expression in retinoblastoma cell lines. Invest. Ophthalmol. Vis. Sci. 2019;60(9):4940.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Rod-derived cone viability factor (RdCVF) is a rod-derived protein that enables cone photoreceptor survival by binding to BSG1/GLUT1 and stimulating aerobic glycolysis. It is normally produced solely in rods from an unspliced (i.e., intron-retaining) isoform of nucleoredoxin-like 1 (NXNL1) RNA. We recently found that the RNA binding protein nucleolin (NCL) binds specifically to a conserved RNA secondary structure located in the NXNL1 intron suggesting a possible role in NXNL1 intron retention and RdCVF expression. Consistent with this possibility, in the primate retina, rods localized in the periphery of the outer retina express NCL and both the spliced and the unspliced NXNL1 gene products, while the cones at the fovea lack NCL and express only the spliced NXNL1 product, RdCVFL. Whereas NCL and RdCVF are normally expressed solely in rods, both NCL and RdCVF are expressed in retinoblastoma cells that derive from cone precursors following biallelic inactivation of the RB1 gene. Here, we examine whether NCL triggers intron retention and RdCVF expression in retinoblastoma cells.

Methods : After identifying the optimal infection condition with low cytotoxicity, several retinoblastoma cell lines were transduced with NCL shRNAs via lentivirus infection in order to inhibit NCL expression. After that, NCL and RdCVF expression are quantified by RT-PCR.

Results : In three retinoblastoma cell lines with low-, middle-, and high-level chromosomal copy number alterations, the expression of RdCVF and NCL mRNAs is significantly higher than in the primate macula enriched in cone photoreceptors. In these transformed cells we will determine if shRNA-mediated decrease in NCL expression causes decreased NXNL1 intron retention and decreased RdCVF expression.

Conclusions : In retinoblastoma cells, high-level expression of NCL is associated with the expression of the intron retaining NXNL1 mRNA and production of RdCVF protein, as normally occurs in rods. Accordingly, RdCVF could stimulate aerobic glycolysis in an autocrine manner to enable the proliferation of retinoblastoma tumor independently of rod trophic support.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×